Hyperphosphatemia
Conditions
Interventions
Subjects received single dose of about 30 mg of TS-172 containing 1 MBq [14C]TS-172 as an oral solution
Sponsors
Mita Seiji
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: - Japanese males aged >=20 and =18.5 and <25.0 kg/m2 at screening - Subjects who have no abnormal findings in the physical examination, vital signs, and standard 12-lead ECG in the screening test and the test on the day of admission and the test obtained prior to administration of the investigational drug, and whose clinical test results are within the standard values of the clinical trial site in the screening test and the test on the day of admission. However, if who showed abnormal findings or values outside the reference ranges but not clinically significant, they can be enrolled in clinical trials based on comprehensive consideration of medical viewpoints by the principal investigator(s) or subinvestigator(s). - Subjects who understand, and have willingness and ability to read and sign, the informed consent form
Exclusion criteria
Exclusion criteria: - Subjects who have been administered substances labelled with radioisotopes or exposed to high levels of radiation (e.g. CT scan, gastric X-ray, PET scan) within one year prior to dosing of the investigational drug. - Occupationally exposed worker within one year prior to dosing of the investigational drug (e.g. workers who handle nuclear power or radioactive substances) - Subjects who have had 3 days or less that one or more spontaneous defecations (defecation that occurs without laxatives, enemas, disimpaction) within 7 days before consent is obtained or during the 7 days until on the day of admission. Those who have diarrhea during the 7 days until on the day of admission - History of any disease or surgery which have impact on investigational drug absorption such as gastrointestinal ulcer, gastrectomy, gastroenterostomy or bowel resection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Radioactivity concentration in whole blood and plasma - Calculation of cumulative urinary and fecal recovery of total radioactivity, and calculation of mass balance as a sum of the percentages of total radioactivity recovered in urine and faeces - Concentration of unchanged form and its major metabolites in plasma - Percentage of unchanged form and metabolites to total radioactivity in plasma - Percentage of unchanged form and metabolites to total radioactivity in urine and faeces - Metabolite profiling and structural identification of metabolites in plasma, urine and faeces | — |
Contacts
Public ContactDevelopment Management Development Headquarters
Taisho Pharmaceutical Co., LTD.
Outcome results
None listed